{
    "clinical_study": {
        "@rank": "13244", 
        "arm_group": [
            {
                "arm_group_label": "Healthy Controls", 
                "arm_group_type": "Experimental", 
                "description": "healthy controls"
            }, 
            {
                "arm_group_label": "Patients", 
                "arm_group_type": "Experimental", 
                "description": "patients with type 2 diabetes mellitus"
            }
        ], 
        "brief_summary": {
            "textblock": "Single center, 14-day, open-label trial to examine the effect of 25 mg q.d. empagliflozin on\n      kinetics of renal glucose reabsorption in patients diagnosed with type 2 diabetes mellitus\n      and healthy controls"
        }, 
        "brief_title": "Effect of Empagliflozin Kinetics on Renal Glucose Reabsorption in Patients With Type II Diabetes and Healthy Controls", 
        "completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Diabetes Mellitus, Type 2", 
            "Healthy"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n          1. T2DM patients and healthy controls aged =18 to <70 at Visit 1.\n\n          2. Patients diagnosed with T2DM according to the American Diabetes Association criteria\n             prior to informed consent who are drug-na\u00efve\n\n          3. T2DM patients on a stable dose of allowed concomitant medications (as determined by\n             investigator) for 30 days prior to entering the study.\n\n          4. T2DM patients with HbA1c between >7 and <10.0% (>53 mmol/mol and <86 mmol/mol) at\n             Visit\n\n        Exclusion criteria:\n\n          1. Patients with type 1 diabetes mellitus.\n\n          2. Patients with uncontrolled hyperglycemia with a fasting plasma glucose level greater\n             than 240 mg/dl after an overnight fast.\n\n          3. Patients with a history of clinically significant heart disease (New York Heart\n             Classification greater than class 3; more than non-specific ST-T wave changes on the\n             ECG), peripheral vascular disease (history of claudication), or pulmonary disease as\n             determined by investigator.\n\n          4. Medical history of cancer (except for basal cell carcinoma) and/or treatment for\n             cancer within the last 5 years."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 21, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01867307", 
            "org_study_id": "1245.66"
        }, 
        "intervention": [
            {
                "arm_group_label": "Patients", 
                "intervention_name": "Empagliflozin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Healthy Controls", 
                "description": "open label", 
                "intervention_name": "BI 10773", 
                "intervention_type": "Drug"
            }
        ], 
        "lastchanged_date": "May 19, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "San Antonio", 
                    "country": "United States", 
                    "state": "Texas"
                }, 
                "name": "1245.66.01001 Boehringer Ingelheim Investigational Site"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "An Open-label Mechanistic Study to Examine the Effect of Oral Empagliflozin (25 mg q.d.) on Kinetics of Renal Glucose Reabsorption in Patients With Type 2 Diabetes Mellitus and Healthy Controls", 
        "overall_contact": {
            "email": "clintriage.rdg@boehringer-ingelheim.com", 
            "last_name": "Boehringer Ingelheim Call Center", 
            "phone": "1-800-243-0127"
        }, 
        "overall_official": {
            "affiliation": "Boehringer Ingelheim", 
            "last_name": "Boehringer Ingelheim", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Change from baseline of renal tubular maximum reabsorptive capacity for glucose (TmG) at end of empagliflozin treatment (Visit 12)", 
            "safety_issue": "No", 
            "time_frame": "14 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01867307"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Boehringer Ingelheim", 
        "sponsors": {
            "collaborator": {
                "agency": "Eli Lilly and Company", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Boehringer Ingelheim", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}